肺癌
循环肿瘤DNA
肿瘤科
免疫疗法
合并(业务)
医学
放化疗
化疗
置信区间
免疫学
前瞻性队列研究
放射治疗
彭布罗利珠单抗
进行性疾病
疾病
性能状态
生存分析
临床终点
预测标记
循环肿瘤细胞
肺
免疫系统
内科学
作者
Yin Yang,Yuqi Wu,Jingjing Zhao,Tao Zhang,Kailun Fei,Xiaotian Zhao,Lei Deng,Zhihui Zhang,Ying Jiang,Jianyang Wang,Wenyang Liu,Xin Wang,Song Wang,Hua Bao,Xue Wu,Minyi Zhu,Qiuxiang Ou,Wei Tang,Lühua Wang,Zhijie Wang
标识
DOI:10.1038/s41392-025-02445-y
摘要
Despite the lack of predictive biomarkers and a prognostic stratification strategy, immune checkpoint inhibitor (ICI) has shown promise in improving outcomes for patients with limited-stage small cell lung cancer (LS-SCLC). We evaluated the potential of circulating tumor DNA (ctDNA) to dynamically predict outcomes in patients with LS-SCLC receiving concurrent chemoradiotherapy (CCRT) with or without consolidation ICI. We analyzed 490 serial samples collected from 144 LS-SCLC patients at baseline (t0), post-induction chemotherapy and pre-thoracic radiotherapy (t1), post-radiotherapy (t2), and progressive disease (t3). For 44 patients receiving consolidation ICI with serplulimab, an investigational PD-1 inhibitor, ctDNA dynamics during consolidation ICI were also assessed at multiple time points. Patients with undetectable ctDNA after CCRT had good outcomes with or without consolidation ICI, whereas ctDNA-positive patients at t2, indicating poor response to CCRT, derived survival benefit from consolidation ICI. Notably, ctDNA status at t1 appeared more predictive than at t2. A three-level risk stratification strategy integrating t1 ctDNA status with radiological tumor shrinkage identified a high-risk subgroup of patients who achieved significantly improved progression-free survival (PFS) (hazard ratio [HR], 0.24; 95% confidence interval [CI], 0.08-0.75; p = 0.014) and overall survival (OS) (HR, 0.06; 95% CI, 0.00-0.42; p = 0.001) from consolidation ICI, prioritizing CCRT plus consolidation ICI. Furthermore, maintaining ctDNA negativity during consolidation ICI was associated with favorable outcomes. These data provide valuable insights into the individualized management of LS-SCLC in the era of immunotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI